GoAI
Get started
Anbio Biotechnology Class A Ordinary Shares logo

Anbio Biotechnology Class A Ordinary Shares

NNNN

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Regular session

$7.6301

+$0.8201 · +12.04%

Aug 24, 11:18 AM ET

NNNN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

32

Weakening

Sentiment

58

Mixed

Risk resilience

4

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
DE
CEO
Michael Lau
Listed since
Feb 19, 2025
Employees
27

Market position

Day range

Current $7.6301

52-week range

Current $7.6301

Open
$6.77
Previous close
$6.81
Volume
142.06K
2.65× average
Average volume
53.64K
Average daily volume
Market cap
334.89M USD
Beta
5.35
Market reference 1
50-day average
$11.4292
-33.24% below average
200-day average
$23.1396
-67.03% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends94%68%43%18%Gross margin, FY2021: 57.40%Gross margin, FY2022: 53.36%Gross margin, FY2023: 50.07%Gross margin, FY2024: 71.90%Gross margin, FY2025: 87.24%Operating margin, FY2021: 55.46%Operating margin, FY2022: 43.30%Operating margin, FY2023: 29.22%Operating margin, FY2024: 24.38%Operating margin, FY2025: 66.70%Net margin, FY2021: 57.26%Net margin, FY2022: 42.52%Net margin, FY2023: 33.58%Net margin, FY2024: 28.99%Net margin, FY2025: 74.06%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.40%. Gross margin FY2022 53.36%. Gross margin FY2023 50.07%. Gross margin FY2024 71.90%. Gross margin FY2025 87.24%. Operating margin FY2021 55.46%. Operating margin FY2022 43.30%. Operating margin FY2023 29.22%. Operating margin FY2024 24.38%. Operating margin FY2025 66.70%. Net margin FY2021 57.26%. Net margin FY2022 42.52%. Net margin FY2023 33.58%. Net margin FY2024 28.99%. Net margin FY2025 74.06%.

Income trends

Revenue

8.65M USD+5.64%

Operating income

5.77M USD+189.06%

Net income

6.4M USD+169.86%
Income trends across reported periods25.7M USD17.07M USD8.44M USD−197.44K USDRevenue, FY2021: 4.43M USDRevenue, FY2022: 23.54M USDRevenue, FY2023: 6.71M USDRevenue, FY2024: 8.19M USDRevenue, FY2025: 8.65M USDOperating income, FY2021: 2.46M USDOperating income, FY2022: 10.2M USDOperating income, FY2023: 1.96M USDOperating income, FY2024: 2M USDOperating income, FY2025: 5.77M USDNet income, FY2021: 2.54M USDNet income, FY2022: 10.01M USDNet income, FY2023: 2.25M USDNet income, FY2024: 2.37M USDNet income, FY2025: 6.4M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.43M USD. Revenue FY2022 23.54M USD. Revenue FY2023 6.71M USD. Revenue FY2024 8.19M USD. Revenue FY2025 8.65M USD. Operating income FY2021 2.46M USD. Operating income FY2022 10.2M USD. Operating income FY2023 1.96M USD. Operating income FY2024 2M USD. Operating income FY2025 5.77M USD. Net income FY2021 2.54M USD. Net income FY2022 10.01M USD. Net income FY2023 2.25M USD. Net income FY2024 2.37M USD. Net income FY2025 6.4M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.65M USD8.19M USD6.71M USD23.54M USD4.43M USD
Cost of goods sold1.1M USD2.3M USD3.35M USD10.98M USD1.89M USD
Gross profit7.54M USD5.89M USD3.36M USD12.56M USD2.54M USD
Research and development201.31K USD454.23K USD134.7K USD200K USD—
Selling, general, and administrative1.57M USD3.44M USD1.27M USD2.17M USD86.1K USD
Operating expenses1.78M USD3.89M USD1.4M USD2.37M USD86.1K USD
Interest income142.02K USD337.51K USD165.34K USD42.25K USD—
Interest expense———8K USD—
Depreciation and amortization——13.04K USD6.25K USD—
Operating income5.77M USD2M USD1.96M USD10.2M USD2.46M USD
Net income6.4M USD2.37M USD2.25M USD10.01M USD2.54M USD

Company facts updated Aug 24, 2026.

NNNN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

Continue in GoAI

Research NNNN

research.disclaimer